![]() |
|
|
Vol. 284, Issue 1, 312-316, 1998
Biomedical Research Center (T.O., L.L., P.K., R.H., P.I.,
K.K., R.S.), Leiras Oy, Turku, Finland;
Department of Anatomy and
Biocenter (Z.P.), University of Oulu, Finland and
Department of Medical
Cell Biology (K.V.), University of Uppsala, Sweden
The effects of clodronate administered p.o. on bone mineral density
(BMD), bone geometry and strength of bone were investigated in
6-month-old ovariectomized rats. Sixty Sprague-Dawley rats were
randomized into four groups. Three groups were ovariectomized (OVX) and
one group was sham-operated (SHAM). The OVX groups were given p.o.
either clodronate (100 mg/kg/d or 500 mg/kg/d) or a vehicle. The SHAM
group received the vehicle. Treatments started on the day of OVX and
continued for 3 months. BMD of proximal tibial metaphysis was measured
by computed tomography in vivo 1 day before OVX and 6 and 12 weeks after OVX. At the end of the study, left tibiae and femora were
removed for ex vivo BMD and bone geometry measurement. A
three-point bending test of the tibial shaft was carried out, and ash
weights of femur and tibia were determined. OVX induced a marked
decrease in total and trabecular BMD over time at the proximal tibial
metaphysis. This bone loss was prevented by clodronate. Clodronate also
prevented the decrease in BMD and change in bone geometry at distal and
proximal femur, as well as the decrease in total ash weight of femur
and tibia. OVX did not cause any marked changes in cortical BMD or bone
geometry at the level of mid-diaphysis of tibia or femur over a 3-month period. Neither were there any changes between groups in bending strength in the tibial diaphysis. However, a positive correlation (n = 58, r = 0.51, P < .001) was
found between bending strength and calculated density-weighted polar
moment of resistance of tibial diaphysis. We conclude that clodronate
administered p.o. in adult rats prevents changes due to estrogen
deficiency in BMD and bone geometry.